SAN DIEGO, Sept. 21 /PRNewswire/ -- ChemDiv, Inc. (San Diego) announced
today that its Chemical Diversity Research Institute (CDRI, Moscow) is
undertaking a partnership with the Blokhin Russian Oncology Center (RONC)
of the Russian Academy of Medical Sciences, the US Department of Energy
(DOE), and the US National Cancer Institute (NCI) to develop novel small
molecule therapies for the prevention and treatment of prostate cancer
(PRC). The partnership will operate under the auspices of The Global
Initiatives for Proliferation Prevention Program.